^
    Back
    Association details:
    Biomarker:ABCC1 overexpression
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Cells
    Title:

    Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

    Published date:
    02/11/2022
    Excerpt:
    Our findings indicate that upregulation of USP22 and ABCC1 expression during treatment contribute to sorafenib resistance in HCC cells…
    DOI:
    10.3390/cells11040634